For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
On December 16, Morgan Stanley analyst Sanjit Singh initiated coverage of Elastic (ESTC) with an Overweight rating and a $130 price target. The analyst told investors in a research note that ...
The committee noted a recurring theme in the evidence in that overweight and obesity can be complex and multifaceted, and can interact with many areas of a person's life. They agreed on the need to ...
Health and social care professionals should follow our general guidelines for people delivering care: See also the section on classifying overweight, obesity and central adiposity in adults. For a ...